Atigotatug/nivolumab - Bristol-Myers Squibb;
Alternative Names: Atigotatug/nivolumab; BMS-986489; BMS-986489 (BMS-986012+ Nivolumab)Latest Information Update: 06 Feb 2025
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Small cell lung cancer
Most Recent Events
- 29 Jan 2025 Bristol-Myers Squibb plans a phase I trial for Small Cell Lung Cancer (Second-line therapy or greater) in China in July 2025 (NCT06799286)
- 14 Jan 2025 SCRI Development Innovations plans phase II trial in Small cell lung cancer in March 2025 (NCT06773910)
- 17 Oct 2024 Bristol-Myers Squibb plans a phase III trial for Small-cell lung cancer (First line therapy, Combination therapy, Late-stage disease) in USA, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, France, Germany, Greece, India, Italy, Netherlands, Poland, Romania, Spain, Switzerland, Turkey, United Kingdom (Unspecified) in January 2025 (NCT06646276)